Barclays starts Bruker with Overweight after acquisition spree

Barclays initiated coverage of Bruker with an Overweight rating and $75 price target The company’s acquisitions over the past two years has reshaped the portfolio around a more multi-omics approach to research, the analyst tells investors in a research note. The firms says these changes come at a time when customer demand for multi-omics technologies and applications appear to be inflecting. Researchers are moving beyond just looking at genomics and now want a toolkit enabling broader analyses into how proteomics, epigenomics, genomics, and other omics, contends Barclays.